ReviewImmunologic research2018
IL-35: a new immunomodulator in autoimmune rheumatic diseases.
Review in Immunologic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Tissue-resident immune cells drive genetic risk in autoimmune and lung diseases.Nature immunology · 2026Article
- The role and mechanism of IL‑35 in myasthenia gravis (Review).International journal of molecular medicine · 2026Review
- The impact of dyslipidemia on skeletal health - from an immunoregulatory perspective.Frontiers in immunology · 2026Review
- Impact of kynurenine metabolites on B and T cells in multiple sclerosis and allergies.IBRO neuroscience reports · 2025Review
- Serum Levels of IL-35, One of the Newest Members of Interleukin-12 Family of Cytokines, in Patients With Vitiligo.Dermatology practical & conceptual · 2024Article
- Lactococcus lactis as an Interleukin Delivery System for Prophylaxis and Treatment of Inflammatory and Autoimmune Diseases.Probiotics and antimicrobial proteins · 2024Review
- The Inflammatory Contribution of B-Lymphocytes and Neutrophils in Progression to Osteoporosis.Cells · 2023Review
- Reduced circulating interleukin 35 is associated with enhanced peripheral T cell function in primary biliary cholangitis.Biomolecules & biomedicine · 2023Article
- B cells and tumor immune escape.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- The Rising Era of "Immunoporosis": Role of Immune System in the Pathophysiology of Osteoporosis.Journal of inflammation research · 2022Review
- Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity.Journal of clinical medicine · 2021Review
- Epigenetic DNA Methylation ofInternational journal of molecular sciences · 2021Article
- The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α.Annals of translational medicine · 2021Article
- Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3.Cellular and molecular life sciences : CMLS · 2020Article
- IL-35 and RANKL Synergistically Induce Osteoclastogenesis in RAW264 Mouse Monocytic Cells.International journal of molecular sciences · 2020Article
- The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells.Frontiers in immunology · 2020Review
- On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells.Immunologic research · 2019Review
- Rapid Communication: Plasma Interleukin-35 in Children with Autism.Brain sciences · 2019Article
- Bacteroides fragilis polysaccharide A induces IL-10 secreting B and T cells that prevent viral encephalitis.Nature communications · 2019Article
- Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis.Mediators of inflammation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-35 is a relatively new cytokine that emerges as an important immunomodulator. IL-35 belongs to IL-12 cytokine family that includes IL-12, IL-23, IL-27, and IL-35. These cytokines are heterodimers that share subunits and their receptors also share subunits. Whereas IL-12 and IL-23 are clearly proinflammatory cytokines, the role of IL-35 is less clear. In mice, IL-35 appears to be anti-inflammatory and to protect from autoimmune inflammatory diseases. IL-35 induces the expansion of a subset of regulatory T cells (Tregs) and Bregs and mediates their suppressive function and inhibits Th17 cells. It also upregulates osteoprotegerin and suppresses RANKL, thus inhibiting bone resorption. In autoimmune rheumatic diseases, findings are conflicting, although in systemic lupus erythematosus, there is reduced function of IL-35. In psoriatic arthritis, a disease characterized by bone erosion and bone formation in peripheral joints and bone formation in spinal joints, serum levels of IL-35 were found increased in one study. Further data are required to define the exact role of IL-35 in human autoimmune rheumatic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.